We review the largest investment rounds in recent years in Surgical Robotics, a sector with a turnover close to \u20ac5,000M per year and a growth of 30% over the last 5 years. We also analyse the round being prepared by the Catalan company Rob Surgical Systems.<\/p>\n
Get in touch with our experts.<\/p>\n
We review the largest investment rounds in recent years in Surgical Robotics, a sector with a turnover close to \u20ac5,000M per year and a growth of 30% over the last 5 years. We also analyse the round being prepared by the Catalan company Rob Surgical Systems.<\/p>\n
Rob Surgical Systems<\/a> is a spin-off of the Polytechnic University of Catalonia (UPC) and the Institute for Bioengineering of Catalonia (IBEC) created in 2012 in Barcelona. The Catalan start-up has developed its own prototype robot for minimally invasive laparoscopic surgery, called Bitack. With the help of leading international specialists in the field, Rob Surgical has successfully completed technical validation with experimental models and is preparing to obtain European approval, the CE marking, and go to market in 2019.<\/p>\n The company aims to compete with US giant Intuitive Surgical, which is listed on the Nasdaq with a valuation of $$47 billion (\u20ac38.4 billion). Intuitive Surgical had a turnover of $3.1 billion (\u20ac2.533 billion) last year with variants of its DaVinci model.<\/p>\n Bitrack is the modular, flexible and more economical alternative to the Da Vinci robot installed in numerous leading hospitals around the world, such as the Hospital Cl\u00ednico San Carlos in Madrid, the Hospital Universitario Virgen del Roc\u00edo in Seville and the Hospital Universitario Vall d'Hebron in Barcelona, among others.<\/p>\n According to Jaume Amat, co-founder and CEO of Rob Surgical, \"the global challenge of robotic surgery is to improve efficiency; in other words, without sacrificing the effectiveness of current systems, robots can be acquired at a lower cost that meet some of the technical requirements demanded by the medical community. We have set out to make robotic surgery available to most hospitals. We have now completed the R&D phase, led by a scientific and technical team of international prestige, and we have a functional prototype protected by international patents that responds to real market needs. The road ahead to bring it to market and the business model are clear.<\/p>\n <\/p>\n Rob Surgical Systems, a Catalan startup that has developed its own minimally invasive laparoscopic surgery robot prototype, is finalising a \u20ac3M funding round to cover the last phase of the project and go to market in 2019.<\/p>\n To date, Rob Surgical has raised \u20ac2M from private investors and \u20ac1M in public funding.<\/p>\n <\/p>\n Robotic surgery is perceived as a value driver for the patient, the surgeon and the hospital, enabling complex operations to be performed with high precision. It is estimated to be a market with a turnover of close to \u20ac5 billion per year, with an annual growth rate of 30% over the last 5 years. Currently, 99% of the surgical robotics market share is held by the US company Intuitive Surgical.<\/p>\n <\/p>\n\n<\/span>Rob Surgical Systems prepares for \u20ac3M round<\/span><\/h2>\n
<\/span>Analysis of investment in Surgical Robotics<\/span><\/h2>\n